Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 5/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14808786 | 0.89 | EGLN1 (0.42) | EGLN1CYP2C8EGLN2EGLN3CTSV | |
| SCHEMBL14809261 | 0.88 | EGLN1 (0.54) | EGLN1CYP2C8EGLN2EGLN3ACP3 | |
| SCHEMBL14820742 | 0.88 | HPGDS (0.43) | EGLN1ACP3SLC2A1HPGDS | |
| SCHEMBL3406643 | 0.88 | EGLN1 (0.63) | EGLN1CYP2C8EGLN2EGLN3SLC2A1 | |
| SCHEMBL16243670 | 0.86 | CYP3A4 (0.48) | EGLN1CYP2C8EGLN2EGLN3CTSV | |
| SCHEMBL14821261 | 0.86 | EGLN1 (0.47) | EGLN1CYP2C8EGLN2EGLN3ACP3 | |
| SCHEMBL20538492 | 0.85 | EGLN1 (0.55) | EGLN1CYP2C8EGLN2EGLN3SLC2A1 | |
| SCHEMBL3434896 | 0.83 | EGLN1 (0.50) | EGLN1CYP2C8EGLN2EGLN3CTSV | |
| SCHEMBL3430833 | 0.83 | EGLN1 (0.50) | EGLN1CYP2C8EGLN2EGLN3CTSV | |
| SCHEMBL14822227 | 0.82 | EGLN1 (0.49) | EGLN1CYP2C8EGLN2EGLN3CTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758059-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | claimed |
| US-9079930-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-07-14 | — | — | US | claimed |
| US-20140349972-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP (US) | 2014-11-27 | — | — | US | claimed |
| EP-2758059-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | disclosed |
| US-9079930-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079930-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079930-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140349972-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349972-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349972-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP (US) | 2014-11-27 | — | — | US | disclosed |
| EP-2758059-A1 | SUBSTITUTED PYRIMIDINES | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043624-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043624-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013040790-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349972-A1 | SUBSTITUTED PYRIMIDINES | HIF1AN, HIF1A, EGLN3 | EGLN1 7/4885CYP2C8 1401/4885EGLN2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.